Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
10,970 total articles
Chubb (CB) combines conservative balance-sheet metrics, a durable franchise and an attractive valuation near $350 per share. With a strong dividend, a fresh $7.5B buyback and an historical track record of underwriting discipline, Chubb looks set for measured upside. Trade plan included for a long position with clear entry, stop and target tied to t…
Rocket Lab (RKLB) has moved from a pure-play small-launcher into a vertically integrated space company after an $8B Iridium acquisition and a string of defense contracts. The business now has a $2B backlog, growing revenue, and a clear path to recurring mission services. That combination makes the current pullback attractive for a directional long …
Adobe is translating generative AI into product upgrades and new monetization lanes without sacrificing its core Creative Cloud and Experience businesses. At roughly $248, the stock offers a risk/reward skew that favors a long position into an AI-driven upgrade cycle; entry, stop and target are provided with a 180-trading-day horizon.
Antero Resources (AR) shows a constructive technical base above key moving averages, supported by a low leverage profile, strong free cash flow ($765.6M) and attractive valuation (P/E ~10, EV/EBITDA ~5.9). We outline an actionable mid-term long trade with entry, stop and target, explain the fundamental drivers tied to natural gas and midstream stre…
Columbus McKinnon (CMCO) surged on news-flow around a surprisingly strong fiscal Q1, sending the stock well above its recent lows. After a sharp intraday pullback to $19.14, the name now offers a defined entry with a clear stop and a target near the 52-week high. Fundamentals are mixed - solid liquidity and a 2.39% yield offset negative EPS, stretc…
Amazon's latest quarter shows AI-driven AWS strength and $200B+ infrastructure spending starting to translate into revenue and margins. The stock has already ripped higher on the print, but fundamentals and technicals support a disciplined long trade with clear entry, stop and target. This is a long-term trade (180 trading days) sized for investors…
Pfizer's steep valuation discount and sky-high yield have been a focal point for bears. Recent management commentary, cash/investment buffers and neutral-to-bullish technical signals suggest the worst of the dividend panic may be passing. This is a tactical swing trade to capture a near-term re-rating while still respecting capital preservation thr…
<p>SK Hynix is shifting from classic memory-cycle exposure toward a more contractual, infrastructure-like role in AI datacenters. We think the market will increasingly value predictable supply agreements for HBM and specialized DRAM as comparable to other forms of hardware infrastructure revenue. That re-rating provides an asymmetric trade opportun…
BrightSpire's commercial real estate loan book is beginning to show the earnings power investors have been waiting for. The stock yields north of 12% and trades below book, while recent cash flow and falling short interest suggest a window for a mid-term long trade. This idea lays out an entry at $4.95, a stop at $4.30 and a target of $6.15 over a …
Vertiv's Q2 revenue miss has rattled the stock, but the company's core exposure to AI data center power and cooling plus strong cash generation make this a compelling trade. We upgrade to long and lay out a clear entry at $240.20, a $360 target and a $210 stop for a long-term (180 trading days) tactical position.
MongoDB's stock has pulled back from its 52-week highs, but the business metrics that matter - Atlas growth, positive free cash flow of $591M and improving technicals - point to a mid-term buying opportunity. This trade idea outlines an entry at $328.00, a $400 target and a $300 stop, with a primary horizon of 45 trading days and clear catalysts an…
W.P. Carey offers a roughly 5% yield, built-in rent escalators across a 1,700+ net-lease portfolio, and free cash flow that still covers the dividend. The stock trades near mid-range of its 52-week band with reasonable valuation (P/B ~2, P/E ~25.6) and an enterprise value of about $25.6B. We recommend a tactical long: entry $73.56, target $78.00, s…
Telix (TLX) is executing across commercial rollouts and multiple late-stage programs while stitching together a platform approach to radiopharmaceuticals. With Q2 revenue of $247M, Precision Medicine sales of $202M, and FY2026 guidance to exceed $1B, the business is shifting from single-product commercial risk to a scalable radiopharma operating sy…
Microsoft is benefitting from accelerating AI-driven demand in Azure, strong free cash flow and a healthy balance sheet. I lay out an actionable long trade with entry, stop and target that balances momentum with valuation and explicit risk controls.
SoFi reported a breakout quarter of revenue and membership growth, and the numbers argue the company is finally monetizing its
T-Mobile's stock has been pushed lower by headline risk tied to SpaceX's Starlink momentum and investor confusion after Q2 volatility. Fundamentals remain solid: 9% service revenue growth, raised free cash flow guidance to $18.4-18.8B, healthy free cash flow of $18.4B, and an EV/EBITDA of 8.3. This trade idea lays out an actionable long trade with …
Fulcrum (FULC) is a speculative buy after the June discontinuation of pociredir and a subsequent strategic review. Market cap trades below the company's stated cash reserves, the pipeline retains clinical promise and the company has time to execute alternatives. This trade idea outlines entry, stop and targets for a mid-term swing position while fl…
Align Technology (ALGN) trades at a reasonable multiple vs. its growth profile and has positive operational signs — record Invisalign submissions and activist interest — but topline momentum remains tepid. This trade idea outlines a long entry on a pullback, clear risk controls, and what to watch over a 180-trading-day horizon.
Innate Pharma (IPHA) trades at roughly $168M market cap with multiple clinical-stage assets in oncology. The shares sit near $1.75 after pulling back from a $2.62 52-week high; average volumes are low and short interest has been meaningful. For traders willing to accept binary clinical and financing risk, a controlled long swing (mid term, 45 tradi…
Penguin Solutions reported a blowout Q3 with 48% revenue growth to $479M and raised full-year guidance, signaling durable demand for its memory and AI infrastructure products. Valuation is elevated but supported by accelerating gross margins and pricing power as memory supply tightness benefits vendors focused on AI workloads. We outline a mid-term…
SK hynix has been punished with a cascade of weak sentiment that looks priced for a worst-case memory depression. I upgrade to Buy: this is a tactical, data-driven play on improving DRAM/NAND fundamentals, inventory destocking ending, and an easily imaginable earnings rebound. Trade plan included with exact entry, stop and target for a mid-term swi…
Veeva's recent pullback after a solid Q1 print looks like an opportunity. The company reported EPS of $2.24 and revenue of $882.95M on 06/03/2026, raised FY2027 guidance, and sits on healthy cash flow. At the same time the stock trades at elevated multiples and investors have priced strong future growth. We rate VEEV a buy from $201.54 with a defin…
AeroVironment (AVAV) has been punished on program stops and litigation headlines, but balance-sheet resilience, a steady pipeline of counter-UAS and loitering munition contracts, and improving technicals suggest the bottom may be forming. This trade idea outlines a disciplined long with entry at current levels, a stop below the recent low, and a ta…
IonQ's headline metrics look frothy, but two questions - can the company sustain hyper-growth in commercial quantum services and does it have a cash runway to get there - have answers that justify a tactical long. Strong top-line momentum, a $3.0B cash war chest and improving technicals make this a high-risk, high-reward long idea with defined risk…
Eastman Chemical (EMN) reported the kind of operational resilience that matters for a cyclical specialty-chemicals name: solid free cash flow, a manageable balance sheet, and pricing power from regional feedstock tightness tied to Middle East supply disruptions. At a market cap just over $8.0B and EV/EBITDA near 9.2x, the stock looks reasonably val…
